Status: Recruiting
A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined With Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.
This is a single-centre, single-arm, open-label, early clinical study to evaluate the safety, tolerability and preliminary efficacy of donor NK cells injection combined with low-dose interleukin-2 in the treatment of acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Participants needed: 12
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Peking University First HospitalUpdated: Aug 5, 2026Locations: 1
Eligibility criteria
Age ≥ 18 years old,; [+4]
Central nervous system involved; [+7]